Literature DB >> 26559594

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

Guido V Bloemberg1, Peter M Keller, David Stucki, David Stuckia, Andrej Trauner, Sonia Borrell, Tsogyal Latshang, Mireia Coscolla, Thomas Rothe, Rico Hömke, Claudia Ritter, Julia Feldmann, Bettina Schulthess, Sebastien Gagneux, Erik C Böttger.   

Abstract

Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26559594      PMCID： PMC4681277          DOI： 10.1056/NEJMc1505196

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


  4 in total

1.  Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis.

Authors:  Dmitri Shcherbakov; Rashid Akbergenov; Tanja Matt; Peter Sander; Dan I Andersson; Erik C Böttger
Journal:  Mol Microbiol       Date:  2010-06-01       Impact factor: 3.501

2.  Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients.

Authors:  Gang Sun; Tao Luo; Chongguang Yang; Xinran Dong; Jing Li; Yongqiang Zhu; Huajun Zheng; Weidong Tian; Shengyue Wang; Clifton E Barry; Jian Mei; Qian Gao
Journal:  J Infect Dis       Date:  2012-09-14       Impact factor: 5.226

3.  Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes.

Authors:  Iñaki Comas; Sonia Borrell; Andreas Roetzer; Graham Rose; Bijaya Malla; Midori Kato-Maeda; James Galagan; Stefan Niemann; Sebastien Gagneux
Journal:  Nat Genet       Date:  2011-12-18       Impact factor: 38.330

Review 4.  Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options.

Authors:  Alimuddin Zumla; Ziad A Memish; Markus Maeurer; Matthew Bates; Peter Mwaba; Jaffar A Al-Tawfiq; David W Denning; Frederick G Hayden; David S Hui
Journal:  Lancet Infect Dis       Date:  2014-09-01       Impact factor: 25.071
  4 in total
  108 in total

1.  In Vitro Study of Stepwise Acquisition of rv0678 and atpE Mutations Conferring Bedaquiline Resistance.

Authors:  Shaheed V Omar; Remco P H Peters; Nabila Ismail; Nazir A Ismail
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Real-Time Sequencing of Mycobacterium tuberculosis: Are We There Yet?

Authors:  Robyn S Lee; Madhukar Pai
Journal:  J Clin Microbiol       Date:  2017-03-15       Impact factor: 5.948

Review 3.  Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions.

Authors:  Gregory M Cook; Kiel Hards; Elyse Dunn; Adam Heikal; Yoshio Nakatani; Chris Greening; Dean C Crick; Fabio L Fontes; Kevin Pethe; Erik Hasenoehrl; Michael Berney
Journal:  Microbiol Spectr       Date:  2017-06

4.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Authors:  Suha Kadura; Nicholas King; Maria Nakhoul; Hongya Zhu; Grant Theron; Claudio U Köser; Maha Farhat
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

Review 5.  Drug-resistance in Mycobacterium tuberculosis: where we stand.

Authors:  Amanda Mabhula; Vinayak Singh
Journal:  Medchemcomm       Date:  2019-06-11       Impact factor: 3.597

Review 6.  Ecology and evolution of Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux
Journal:  Nat Rev Microbiol       Date:  2018-02-19       Impact factor: 60.633

Review 7.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

8.  Mutations in fbiD (Rv2983) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis.

Authors:  Dalin Rifat; Si-Yang Li; Thomas Ioerger; Keshav Shah; Jean-Philippe Lanoix; Jin Lee; Ghader Bashiri; James Sacchettini; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 9.  ESX secretion systems: mycobacterial evolution to counter host immunity.

Authors:  Matthias I Gröschel; Fadel Sayes; Roxane Simeone; Laleh Majlessi; Roland Brosch
Journal:  Nat Rev Microbiol       Date:  2016-09-26       Impact factor: 60.633

10.  Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis.

Authors:  Masaji Okada; Yoko Kita; Satomi Hashimoto; Hitoshi Nakatani; Shiho Nishimastu; Yumiko Kioka; Yasuko Takami
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.